Fate Therapeutics Inc. (NASDAQ: FATE) presented updated clinical data from its Phase 1 trial of FT819, an off-the-shelf CAR T-cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE